Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$4.22 USD
-0.07 (-1.63%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $4.21 -0.01 (-0.24%) 7:58 PM ET
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVXL 4.22 -0.07(-1.63%)
Will AVXL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVXL
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
Other News for AVXL
Acadia Pharmaceuticals: Back In The Buy Zone
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Akero Therapeutics (AKRO)
Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030